Lai Ke-Peng, Huang Qin-Yuan, Lin Kung-Hung, Kou Hwang-Shang, Wang Chun-Chi
School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, 807, Taiwan.
School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, 807, Taiwan; Department of Surgery, Zuoying Armed Forces General Hospital, Kaohsiung, 813, Taiwan; Department of Family Medicine, Zuoying Armed Forces General Hospital, Kaohsiung, 813, Taiwan.
Talanta. 2026 Jan 1;297(Pt B):128734. doi: 10.1016/j.talanta.2025.128734. Epub 2025 Aug 22.
The identification of single-nucleotide variations remains a significant challenge in genetic research due to their high similarity to wild-type DNA sequences. Many conventional approaches rely on sophisticated instrumentation or costly reagents, which limits their accessibility and broad application. To overcome these limitations, a novel detection strategy grounded in the well-established principle of restriction fragment length polymorphism (RFLP) was developed. In contrast to traditional electrophoresis-based RFLP methods, our approach employs biotin-labeled primers in conjunction with magnetic beads to enable efficient and instrument-free fragment separation. An additional advantage of this method lies in its label-free fluorescent detection, which reduces reagent costs and avoids signal interference commonly associated with fluorophore labeling. The system was validated by detecting the EGFR L858R mutation in genomic DNA from non-small cell lung cancer (NSCLC) patients. The method exhibited excellent linearity (r = -0.9995) and recovery rates between 85 % and 105 % in clinical sample analysis. The limit of detection for the L858R mutation ratio was determined to be 1.66 %, positioning the method comparably to commercial real-time PCR kits and next-generation sequencing (NGS) technologies. Compared to our earlier platform, this approach simplifies the workflow by eliminating probe washing and alleviating concerns about enzymatic inhibition caused by magnetic bead immobilization. Furthermore, this platform offers flexibility and can be readily adapted to detect a wide range of clinically relevant mutations through the selection of appropriate restriction enzymes. The simplicity of this method suggests significant potential for its application in point-of-care testing (POCT), particularly in clinical settings that are resource-limited or decentralized.
由于单核苷酸变异与野生型DNA序列高度相似,其鉴定在基因研究中仍然是一项重大挑战。许多传统方法依赖于复杂的仪器或昂贵的试剂,这限制了它们的可及性和广泛应用。为了克服这些限制,基于成熟的限制性片段长度多态性(RFLP)原理开发了一种新型检测策略。与传统的基于电泳的RFLP方法不同,我们的方法使用生物素标记的引物结合磁珠来实现高效且无需仪器的片段分离。该方法的另一个优点在于其无标记荧光检测,这降低了试剂成本并避免了通常与荧光团标记相关的信号干扰。通过检测非小细胞肺癌(NSCLC)患者基因组DNA中的EGFR L858R突变对该系统进行了验证。该方法在临床样本分析中表现出出色的线性(r = -0.9995),回收率在85%至105%之间。L858R突变率的检测限确定为1.66%,该方法与商业实时PCR试剂盒和下一代测序(NGS)技术相当。与我们早期的平台相比,该方法通过省去探针洗涤并减轻对磁珠固定化引起的酶抑制的担忧,简化了工作流程。此外,该平台具有灵活性,通过选择合适的限制性酶可以很容易地用于检测广泛的临床相关突变。该方法的简单性表明其在即时检测(POCT)中具有巨大的应用潜力,特别是在资源有限或分散的临床环境中。